Nanoconjugate Strategy Integrating Immunogenic Cell Death Induction and Innate Immune Activation for Potent Anti‐Cancer Immunity
Advanced Materials · 2026-11 · 38 (63)
DOI: 10.1002/adma.74918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 29.09.2026. Verfasst von Tengyu He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Immunogenic Cell Death, Immunity, Innate, Nanoconjugates, Neoplasms. Die Arbeit nennt 69 Literaturangaben. Gefördert von: Brigham and Women's Hospital Discretionary Research Funds.
Abstract (Originalsprache)
In vivo immune modulation can potentially benefit broader cancer patients. Efficient cross‐priming of anti‐tumor T cells requires “three‐signal” dendritic cells (DCs) that simultaneously integrate antigenic, co‐stimulatory, and migratory programs, which remains a major challenge. Here, we developed a carrier‐free peptide–cyclic dinucleotide (CDN) nanoconjugate (PCN) that co‐activates immunogenic cell death (ICD) in tumors and stimulator of interferon genes (STING) signaling in DCs. Library screening identified ICD‐inducing peptides enriched in hydrophobic and cationic residues that promote self‐assembly, cell penetration, and ICD potency. Mechanistic studies revealed peptides can trigger overlapping pyroptosis, necroptosis, and apoptosis, with lysosomal damage and cathepsin release as dominant upstream drivers. PCN promoted tumor‐antigen release and facilitated cytosolic CDN delivery for robust STING activation. This dual functionality induced early cytokine and chemokine responses and generated cDC1‐enriched “three‐signal” migratory DCs trafficking from tumors to draining lymph nodes, resulting in enhanced antigen‐specific CD8 + T‐cell activation and memory formation. PCN also broadly reprogrammed the tumor microenvironment toward anti‐tumor immunity. In preclinical models, PCN induced complete tumor rejection in 70% of B16‐F10‐ or CT26‐bearing mice and provided durable protection against tumor rechallenge when combined with α ‐PD‐1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA.
- Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
ORCID-Profile: Tengyu He, Daniela Simental Lopez, Zhenyu Han, Erin M O'Brien, Yongkuk Park, Eliz Amar-Lewis, Natalie Artzi
Förderung
- Brigham and Women's Hospital Discretionary Research Funds
Zitieren
APA
He, T., Cryer, A. M., Simental Lopez, D., Han, Z., O'Brien, E. M., Park, Y., Vargas Franyuti, S., Amar-Lewis, E., & Artzi, N. (2026). Nanoconjugate Strategy Integrating Immunogenic Cell Death Induction and Innate Immune Activation for Potent Anti‐Cancer Immunity. Advanced Materials, 38(63). https://doi.org/10.1002/adma.74918
Vancouver
He T, Cryer AM, Simental Lopez D, Han Z, O'Brien EM, Park Y, et al. Nanoconjugate Strategy Integrating Immunogenic Cell Death Induction and Innate Immune Activation for Potent Anti‐Cancer Immunity. Advanced Materials. 2026;38(63). doi:10.1002/adma.74918
BibTeX
@article{He2026,
author = {He, Tengyu and Cryer, Alexander M and Simental Lopez, Daniela and Han, Zhenyu and O'Brien, Erin M and Park, Yongkuk and Vargas Franyuti, Silvia and Amar-Lewis, Eliz and Artzi, Natalie},
title = {Nanoconjugate Strategy Integrating Immunogenic Cell Death Induction and Innate Immune Activation for Potent Anti‐Cancer Immunity},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {63},
doi = {10.1002/adma.74918}
}
EUVIMED